BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ChinaBio(R) LLC Week in Review: China's Rx Market to Total $315 Billion in 2020


8/5/2013 8:42:49 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

by Richard Daverman, PhD

August 3, 2013 --China’s prescription drug market will total $315 billion in 2020, expanding at a 26% compound annual growth rate from $48 billion in 2012, according to GlobalData; aTyr Pharma, a San Diego startup with a Hong Kong subsidiary, completed a $49 million round to fund its protein drug program; Daewoong Pharma will pay $16 million to acquire Liaoning Baifeng; Foundation Medicine, a US company backed by WuXi PharmaTech, filed for an $86.3 million IPO on NASDAQ; Shanghai Pharma entered an agreement with Shanghai’s Secondary Military Medical University to promote translational medicine; Takeda Pharma was granted CFDA approval for Nesina, a DPP-4 treatment for type 2 diabetes; InSightec Ltd. of Israel reported its ExAblate System, a uterine fibroid treatment, was approved for China marketing; China's State Intellectual Property Office invalidated the patent for Viread, a treatment for HBV and HIV/AIDS developed by Gilead Sciences; and Johnson & Johnson was ordered to pay a fine for enforcing a minimum price policy on its China medical products distributors. More details….

Stock Symbols: (NYSE: WX) (SHA: 601607; HK: 2607) (TO: 4502) (NSDQ: GILD) (NYSE: JNJ)

Help employers find you! Check out all the jobs and post your resume.


Read at ChinaBio Today

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES